Dravet Syndrome Overview

Save information for later
Sign Up

Learn About Dravet Syndrome

What is the definition of Dravet Syndrome?
Dravet syndrome is the most severe of a group of conditions known as SCN1A-related seizure disorders. Symptoms include seizures which first occur in infancy that are often triggered by high temperatures (febrile seizures). In childhood, many types of seizures may occur and they may increase in frequency. Seizures may be difficult to treat. Other symptoms include loss of motor skills, intellectual disability, speech impairment, and difficulty with movement. Most cases of Dravet syndrome occur when the SCN1A gene is not working correctly. It can be inherited in an autosomal dominant pattern, but most people with Dravet syndrome do not have a family history of the condition. Diagnosis is based on a clinical exam, medical history, and the results of genetic testing.
What are the alternative names for Dravet Syndrome?
  • Dravet syndrome
  • Myoclonic epilepsy, severe, of infancy
  • SME
  • SMEI
  • Severe Myoclonic Epilepsy of Infancy
Who are the top Dravet Syndrome Local Doctors?
Elite in Dravet Syndrome
Dr. Orrin Devinsky
Neurology | General Surgery
Elite in Dravet Syndrome
Dr. Orrin Devinsky
Neurology | General Surgery

New York University

223 E 34th St, 
New York, NY 
646-558-0800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Orrin Devinsky is a Neurologist and a General Surgeon in New York, New York. Dr. Devinsky is rated as an Elite provider by MediFind in the treatment of Dravet Syndrome. His top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Seizures, Epilepsy, and Deep Brain Stimulation.

Rajdeep Singh
Distinguished in Dravet Syndrome
Dr. Rajdeep Singh
Neurology
Distinguished in Dravet Syndrome
Dr. Rajdeep Singh
Neurology

Atrium Health Neurology Specialty Care

1225 Harding Place, Suite 4200, 
Charlotte, NC 
704-468-0101
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajdeep Singh is a Neurologist in Charlotte, North Carolina. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Dravet Syndrome. His top areas of expertise are Seizures, Memory Loss, Dravet Syndrome, and Epilepsy. Dr. Singh is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Dravet Syndrome
Dr. Joseph E. Sullivan
Pediatric Neurology | Neurology
Elite in Dravet Syndrome
Dr. Joseph E. Sullivan
Pediatric Neurology | Neurology
400 Parnassus Ave Fl 8, Box 0348, 
San Francisco, CA 
415-353-2437
Languages Spoken:
English
See accepted insurances

Joseph Sullivan is a Pediatric Neurologist and a Neurologist in San Francisco, California. Dr. Sullivan is rated as an Elite provider by MediFind in the treatment of Dravet Syndrome. His top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Epilepsy with Myoclonic-Atonic Seizures, and Epilepsy.

View All Doctors
What are the latest Dravet Syndrome Clinical Trials?
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Other
Study Phase: Phase 3

Summary: The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)
Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)
Enrollment Status: Recruiting
Publish Date: September 25, 2025
Intervention Type: Drug

Summary: This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics. The eligible participants are expected to participate in the study for a duration of 52 weeks of treatment.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center